Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
Ultragenyx (NASDAQ: RARE) announced that Emil D. Kakkis, M.D., Ph.D., CEO and president, will present at the 44th Annual J.P.
Rhea-AI Summary
Ultragenyx (NASDAQ: RARE) announced that Emil D. Kakkis, M.D., Ph.D., CEO and president, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 AM PT. A live webcast and archived replay will be available via the company investor website at https://ir.ultragenyx.com/events-presentations. The webcast replay will remain accessible for 30 days following the presentation.
Positive
- None.
Negative
- None.
Details
News Market Reaction – RARE
On Jan 8, the first trading day after this news, RARE closed 4.09% below the previous close.
Data tracked by StockTitan Argus for the Jan 8 session.
Key Figures
- Q3 2025 revenue
- $159.9M
- Quarter ended Sep 30, 2025; up from $139.5M prior year
- Q3 2025 net loss
- $180.4M (EPS -$1.81)
- Quarter ended Sep 30, 2025; wider than $133.5M prior year
- Crysvita revenue
- $111.9M
- Q3 2025 across product sales and royalties
- Cash and equivalents
- $202.5M
- As of Q3 2025 balance sheet
- Marketable debt securities
- $244.8M
- Current and non‑current, as of Q3 2025
- Royalty liabilities
- $829.3M
- Liabilities for sales of future royalties, Q3 2025
- Royalty deal proceeds
- $400M
- Cash received from OMERS affiliate for Crysvita royalty interest
- Royalty cap amount
- $620M
- Total to be received by OMERS at 1.55x purchase price
Historical Context
-
Completed DTX401 BLA submission to FDA supported by Phase 3 data.
-
Setrusumab Phase 3 trials missed primary fracture-rate endpoints.
-
Granted 13,144 RSUs to new non-executive officers under inducement plan.
-
Participation in Citi and Evercore ISI healthcare investor conferences.
-
Granted 18,180 RSUs to newly hired non-executive officers.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 10:30 AM PT.
The live and archived webcast of the presentation will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the webcast will be available for 30 days.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact – Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.